Sunesis Pharmaceuticals (SNSS) Earning Somewhat Favorable Media Coverage, Accern Reports
Headlines about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.3386595419714 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) traded down 3.29% during mid-day trading on Tuesday, hitting $2.06. 90,130 shares of the stock traded hands. The company’s market cap is $48.44 million. Sunesis Pharmaceuticals has a one year low of $2.00 and a one year high of $5.00. The stock has a 50 day moving average price of $2.28 and a 200-day moving average price of $3.07.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.35. During the same period last year, the business earned ($0.12) earnings per share. On average, analysts forecast that Sunesis Pharmaceuticals will post ($1.61) earnings per share for the current fiscal year.
SNSS has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Thursday, August 24th. ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a research report on Thursday, July 27th.
TRADEMARK VIOLATION WARNING: “Sunesis Pharmaceuticals (SNSS) Earning Somewhat Favorable Media Coverage, Accern Reports” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/sunesis-pharmaceuticals-snss-earning-somewhat-favorable-media-coverage-accern-reports/1574123.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.